Taysha Gene Therapies Inc (TSHA)
3.14
+0.03
(+0.96%)
USD |
NASDAQ |
May 16, 16:00
3.15
+0.01
(+0.32%)
After-Hours: 06:35
Taysha Gene Therapies Cash from Financing (Quarterly): -0.022M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -0.022M |
| December 31, 2023 | -4.248M |
| September 30, 2023 | 140.63M |
| June 30, 2023 | 0.377M |
| March 31, 2023 | -0.37M |
| December 31, 2022 | 41.23M |
| September 30, 2022 | -0.103M |
| June 30, 2022 | 11.08M |
| March 31, 2022 | -0.107M |
| Date | Value |
|---|---|
| December 31, 2021 | 9.105M |
| September 30, 2021 | 29.98M |
| June 30, 2021 | 0.00 |
| March 31, 2021 | 0.00 |
| December 31, 2020 | -1.482M |
| September 30, 2020 | 274.18M |
| June 30, 2020 | 0.338M |
| March 31, 2020 | 18.03M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-4.248M
Minimum
Dec 2023
274.18M
Maximum
Sep 2020
30.51M
Average
0.338M
Median
Jun 2020
Cash from Financing (Quarterly) Benchmarks
| Aquestive Therapeutics Inc | 81.74M |
| Lifecore Biomedical Inc | 40.93M |
| Relmada Therapeutics Inc | 0.2217M |
| ACADIA Pharmaceuticals Inc | 1.043M |
| Cyclacel Pharmaceuticals Inc | 0.999M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -19.80M |
| Cash from Investing (Quarterly) | -0.14M |
| Free Cash Flow | -76.24M |
| Free Cash Flow Per Share (Quarterly) | -0.0862 |
| Free Cash Flow to Equity (Quarterly) | -19.94M |
| Free Cash Flow Yield | -15.97% |